nAMD
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
InnoVec BiotherapeuticsChina - Beijing
1 program1
IVB103 Injection（Low dose）Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
2030
2031
InnoVec BiotherapeuticsIVB103 Injection（Low dose）
Clinical Trials (1)
Total enrollment: 18 patients across 1 trials
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
Start: Apr 2025Est. completion: Dec 203118 patients
Phase 1Enrolling By Invitation
Related Jobs
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.